Literature DB >> 18549318

Maximizing dendritic cell migration in cancer immunotherapy.

Pauline Verdijk1, Erik H J G Aarntzen, Cornelis J A Punt, I Jolanda M de Vries, Carl G Figdor.   

Abstract

BACKGROUND: The success of dendritic cell (DC)-based immunotherapy in inducing cellular immunity against tumors is highly dependent on accurate delivery and trafficking of the DC to T-cell-rich areas of secondary lymphoid tissues.
OBJECTIVE: To provide an overview of DC migration in vivo and how migration to peripheral lymph nodes might be improved to optimize DC therapy.
METHODS: We focused on DC migration in preclinical models and human skin explants and on clinical vaccination trials studying migration of in vitro-generated DC. RESULTS/
CONCLUSIONS: DC migration requires an intricate interplay between the cell and its environment. To maximize migration for cellular therapy, it is important to optimize the generation of migratory DC as well as treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549318     DOI: 10.1517/14712598.8.7.865

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  20 in total

Review 1.  Taking the lymphatic route: dendritic cell migration to draining lymph nodes.

Authors:  Alvaro Teijeira; Erica Russo; Cornelia Halin
Journal:  Semin Immunopathol       Date:  2014-01-09       Impact factor: 9.623

Review 2.  Chemokines: can effector cells be redirected to the site of the tumor?

Authors:  Steven M Dubinett; Jay M Lee; Sherven Sharma; James J Mulé
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

Review 3.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

4.  Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Authors:  Norimasa Matsushita; Hiroshi Komine; Annabelle Grolleau-Julius; Shari Pilon-Thomas; James J Mulé
Journal:  Cancer Immunol Immunother       Date:  2010-01-08       Impact factor: 6.968

5.  Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.

Authors:  Sébastien Anguille; Evelien L J M Smits; Nathalie Cools; Herman Goossens; Zwi N Berneman; Vigor F I Van Tendeloo
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

Review 6.  Dendritic cells: a critical player in cancer therapy?

Authors:  Anna Karolina Palucka; Hideki Ueno; Joseph Fay; Jacques Banchereau
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

7.  Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells.

Authors:  Rémi J Creusot; Shahriar S Yaghoubi; Pearl Chang; Justine Chia; Christopher H Contag; Sanjiv S Gambhir; C Garrison Fathman
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

8.  Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Authors:  Vivek Subbiah; Ravi Murthy; David S Hong; Robert M Prins; Chitra Hosing; Kyle Hendricks; Deepthi Kolli; Lori Noffsinger; Robert Brown; Mary McGuire; Siquing Fu; Sarina Piha-Paul; Aung Naing; Anthony P Conley; Robert S Benjamin; Indreshpal Kaur; Marnix L Bosch
Journal:  Clin Cancer Res       Date:  2018-07-17       Impact factor: 12.531

9.  Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.

Authors:  Briana Jill Williams; Shilpa Bhatia; Lisa K Adams; Susan Boling; Jennifer L Carroll; Xiao-Lin Li; Donna L Rogers; Nikolay Korokhov; Imre Kovesdi; Alexander V Pereboev; David T Curiel; J Michael Mathis
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

10.  Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation.

Authors:  Carlos Alfaro; Natalia Suárez; Ivan Martínez-Forero; Asís Palazón; Ana Rouzaut; Sarai Solano; Esperanza Feijoo; Alfonso Gúrpide; Elixabet Bolaños; Lorena Erro; Juan Dubrot; Sandra Hervás-Stubbs; Alvaro Gonzalez; Jose Luis Perez-Gracia; Ignacio Melero
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.